Expanded Access Program (EAP) in Leber's Hereditary Optic Neuropathy (LHON) Patients Treated for 24 Months (Video)
Creator
Thomas Klopstock; Xavier Llòria; Magda Silva; Rudolph Guenther; Felice Lob; Bettina Von Livonius; Claudia Catarino
Affiliation
(TK) Friedrich-Baur-Institute, Dept. of Neurology University of Munich, MUNICH, Germany; (XL) (MS) Santhera Pharmaceuticals Ltd, Pratteln, Switzerland, Pratteln, Switzerland; (RG) (FL) (BV) (CC) Dep of Ophthalmology, University Hospital of the Ludwig-Maximilians University, Munich, Germany
Subject
Optic Neuropathy
Description
LHON is a mitochondrial genetic disorder resulting in severe bilateral central VA loss. Three primary mitochondrial DNA mutations cause over 90% of cases. Data from idebenone EAP for patients with LHON receiving treatment for at least 24 months were analyzed to assess rate of clinically-relevant recovery (CRR).
Date
2020-03
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2020 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS Annual Meeting 2020: Scientific Platform Session III
